aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Korro Bio, founded with the mission to transform scientific insights into life-altering treatments, focuses on pioneering RNA editing to revolutionize patient care. The company’s core vision is to rewrite the future of medicine through its innovative RNA editing platform, Oligonucleotide Promo. This technology aims to address the inherent complexities of first-generation editing approaches, offering new therapeutic possibilities for a range of conditions. Korro Bio targets the biotechnology and pharmaceutical markets, striving to deliver groundbreaking treatments that significantly improve patient outcomes.
Notable figures affiliated with Korro Bio include leading scientists and industry experts who contribute to its cutting-edge research and development. The company has garnered attention from prominent investors in the biotech sector, underscoring its potential impact. Key achievements include advancements in RNA editing technologies and the development of promising therapeutic candidates. Korro Bio's work has the potential to make a profound impact on the treatment landscape, offering hope and new possibilities for patients with previously untreatable conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Treatments, RNA Editing
Technology
HealthTech, Biotech
Tags
Biotech
Model Types
Recurring
Revenue Type(s)
Enterprise
Customer Type(s)
Global
When was Korro Bio founded?
Korro Bio was founded in 2018.
Where is Korro Bio’s headquarters located?
Korro Bio’s headquarters is located in Cambridge, MA, US.
When was Korro Bio’s last funding round?
Korro Bio’s most recent funding round was for $116M (USD) in January 2022.
How many employees does Korro Bio have?
Korro Bio has 99 employees as of Feb 5, 2024.
How much has Korro Bio raised to-date?
As of July 05, 2023, Korro Bio has raised a total of $207.5M (USD) since Jan 5, 2022.
Add Comparison
Total Raised to Date
$207.5M
USD
Last Update Jan 5, 2022
Last Deal Details
$116M
USD
Jan 5, 2022
Series B
Total Employees Over Time
99
As of Feb 2024
Korro Bio Address
400 Technology Square
10th Floor
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts